ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0426

The Clinical Efficacy of Switching Therapy Between Biological Agents and JAK Inhibitors in the Patients with Rheumatoid Arthritis

Tomokazu Choshi1, Kenji Mamoto1, Yutaro Yamada1, Tadashi Okano1, Shohei Anno2, Kazuki Orita2, Takahiro Iida3, Masahiro Tada4, Kentaro Inui5, Tatsuya Koike6 and Hiroaki Nakamura1, 1Osaka Metropolitan University, Osaka, Japan, 2Yodogawa Christian Hospital, Osaka, Japan, 3Koryokai Hospital, Osaka, Japan, 4Osaka City General Hospital, Osaka, Japan, 5Saiseikai Nakatsu Hospital, Osaka, Japan, 6Search Institute for Bone and Arthritis Disease (SINBAD), Shirahama Foundation for Health and Welfare, Shirahama, Japan

Meeting: ACR Convergence 2023

Keywords: Biologicals, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0423–0459) RA – Treatments Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Some patients with rheumatoid arthritis (RA) need switching therapy between biologic agents (Bio) and Janus kinase inhibitors (JAKi) when efficacy of Bio or JAKi is not enough.

The aim of this study was to investigate the clinical efficacy of switching therapy between Bio and JAKi in the patients with RA.

Methods: We evaluated inflammatory markers and disease activities for 12 weeks (W) after switching in the patients with RA who received the switching therapy from Tumor Necrosis Factor inhibitors (TNFi) to JAKi (TNFi-JAKi group, N=61; mean age 64.6±12.9 years old), from Interleukin-6 inhibitors (IL-6i) to JAKi (IL-6i-JAKi group, N=33; mean age 64.9±14.7 years old), and from JAKi to IL-6i (JAKi-IL-6i group, N=8; mean age 65.5±14.7 years old).

Results: The mean values of Matrix Metalloproteinase-3 (MMP-3) (ng/ml) of TNFi-JAKi, IL-6i-JAKi, and JAKi-IL-6i groups were 213.5±481.3, 237.5±179.4, and 268.5±138.4 at baseline (BL), and 118.9±126.3 (p=0.148), 183.6±192.7 (p=0.279), and 196.2±100.9 (p=0.254) after 4W (vs BL), and 104.0±96.1 (p=0.089), 176.6±120.8 (p=0.123), and 137.4±114.5 (p=0.077) after 12W (vs BL), respectively. The mean Disease Activity Score 28- C reactive protein (DAS28-CRP) of TNFi-JAKi, IL-6i-JAKi, and JAKi-IL-6i groups were 4.22±1.27, 4.13±1.39, and 4.87±1.35 at BL, and 3.28±1.37 (p< 0.001), 3.41±1.46 (p=0.805), and 3.24±1.85 (p=0.065) after 4W (vs BL), and 2.99±1.24 (p< 0.001), 3.56±1.45 (p=0.115), and 2.60±1.40 (p=0.005) after 12W (vs BL), respectively (Figure 1). The mean Clinical Disease Activity Index (CDAI) of TNFi-JAKi, IL-6i-JAKi, and JAKi-IL-6i groups were 19.8±11.8, 23.2±12.7, and 21.8±9.9 at BL, and 12.8±10.4 (p< 0.001), 15.7±12.5 (p=0.020), and 14.2±13.9 (p=0.228) after 4W (vs BL), and 10.3±9.8 (p< 0.001), 15.2±12.6 (p=0.012), and 8.6±9.5 (p=0.017) after 12W (vs BL), respectively (Figure 1). There were no significant differences in the mean values of MMP-3 for 12W after switching in all groups. The disease activities (both of DAS28-CRP and CDAI) significantly decreased after 4W in TNFi-JAKi group, and after 12W in TNFi-JAKi and JAKi-IL-6i groups (Figure 1). DAS28-CRP and CDAI kept to decrease for 12W after switching in TNFi-JAKi and JAKi-IL-6i groups, however, DAS28-CRP increased and CDAI did not decrease from 4W to 12W after switching in IL-6i-JAKi group (Figure 1).

Conclusion: There have not still been clear indications of the switching therapy between Bio and JAKi in the patients with RA. In this study, it may be considered that the switching therapy from TNFi to JAKi and from JAKi to IL-6i could be effective when RA patients treated with TNFi or JAKi need switching therapy due to insufficient clinical efficacy.

Supporting image 1

Figure 1: DAS28-CRP and CDAI in three groups for 12 weeks after switching


Disclosures: T. Choshi: None; K. Mamoto: None; Y. Yamada: None; T. Okano: None; S. Anno: None; K. Orita: None; T. Iida: None; M. Tada: None; K. Inui: None; T. Koike: None; H. Nakamura: None.

To cite this abstract in AMA style:

Choshi T, Mamoto K, Yamada Y, Okano T, Anno S, Orita K, Iida T, Tada M, Inui K, Koike T, Nakamura H. The Clinical Efficacy of Switching Therapy Between Biological Agents and JAK Inhibitors in the Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/the-clinical-efficacy-of-switching-therapy-between-biological-agents-and-jak-inhibitors-in-the-patients-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-clinical-efficacy-of-switching-therapy-between-biological-agents-and-jak-inhibitors-in-the-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology